RecruitingPhase 4NCT06918054

Hepatoprotective for Children and Adolescent With Acute Lymphoblastic Leukemia

Hepatoprotective Measures for Children and Adolescents With Acute Lymphoblastic Leukemia During Induction Chemotherapy

Sponsor

Ain Shams University

Enrollment

42 participants

Start Date

Nov 17, 2023

Study Type

INTERVENTIONAL

Conditions

Acute Lymphoblastic Leukemia Leukaemia (Acute)

Summary

This current study will implement a proposed whole program of monitoring and prevention acute hepatic injury during the time of induction chemotherapy in children and adolescent with ALL.

Eligibility

Min Age: 2 YearsMax Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether a liver-protective treatment (hepatoprotective agent) can reduce liver damage caused by chemotherapy in children and adolescents with newly diagnosed acute lymphoblastic leukemia (ALL) — the most common type of childhood leukemia. **You may be eligible if...** - You are between 2 and 18 years old - You have been newly diagnosed with acute lymphoblastic leukemia (ALL) - You are currently in the early (induction) phase of chemotherapy - You are being treated at Ain Shams University Hospital **You may NOT be eligible if...** - You have a known chronic liver disease Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIETARY_SUPPLEMENTDietary modification

Patients will follow Mediterranean Diet (MD), this diet is characterized by a high intake of vegetables, fruit, whole cereals, legumes, nuts, and fish and a low intake of red meat and homemade desserts. The main added fat was extra virgin olive oil, with 35-40% kcal from fat (\<10% from saturated fat), 40-44% kcal from carbohydrate, and 20% kcal from protein

DIETARY_SUPPLEMENTSupplementation of omega 3 fatty acids

Supplementation of omega 3 fatty acids ( dose based on weight: \<40 kg-450 mg/day, 40-60 kg-900 mg/day, \>60 kg-1300 mg/day)

Locations(2)

Ain Shams University

Cairo, Egypt

Faculty of Medicine Ain Shams Research Institute- Clinical Research Center (MASRI-CRC)

Cairo, Egypt

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06918054

Related Trials

Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma

NCT062896733 locations

Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma

NCT065337482 locations

Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome

NCT061958911 location

Allogeneic CMV-Specific CD19-CAR T Cells Plus CMV-MVA Triplex Vaccine After Matched Related Donor Hematopoietic Cell Transplant for the Treatment of Patients With High-Risk Acute Lymphoblastic Leukemia

NCT067356901 location

Resistance Exercise and Incretin Mimetic for Cardiometabolic Health in Survivors of ALL With Obesity

NCT072287411 location